Who are the top shareholders of the Arunis Abode?

The top shareholders of Arunis Abode include promoter Deniis Bhupendra Desai with a 0.0% stake, public shareholder Yagnik Bharatkumar Tank with 35.08%, and individual investors holding 28.83%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Arunis Abode include the promoters, with Deniis Bhupendra Desai being the promoter with the highest holding, although his stake is listed as 0.0%. The highest public shareholder is Yagnik Bharatkumar Tank, who holds 35.08% of the shares. Additionally, individual investors collectively hold 28.83% of the company. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Arunis Abode.

Who are in the management team of Arunis Abode?

As of March 2023, the management team of Arunis Abode consists of Dhara Denis Desai (Chairperson & Managing Director), Leena Manish Desai (Independent Director), Megha Pawan Sultania (Independent Director), Chirag J Shah (Non Executive Director), and Garima Mandhania (Company Secretary & Compliance Officer).

As of March 2023, the management team of Arunis Abode includes the following members:<BR><BR>1. Dhara Denis Desai - Chairperson & Managing Director<BR>2. Leena Manish Desai - Independent Director<BR>3. Megha Pawan Sultania - Independent Director<BR>4. Chirag J Shah - Non Executive Director<BR>5. Garima Mandhania - Company Secretary & Compliance Officer<BR><BR>These individuals play key roles in the governance and management of the company.

What does Arunis Abode do?

Arunis Abode Ltd is a micro-cap NBFC focused on real estate and commodities trading, having transitioned from financial brokerage in 2020. As of March 2025, it reported no net profit and has a market cap of Rs 71 Cr.

Overview: <BR>Arunis Abode Ltd is a micro-cap company operating in the Non Banking Financial Company (NBFC) sector, focusing on real estate business and commodities trading.<BR><BR>History: <BR>Incorporated in October 1994, Arunis Abode Ltd was initially engaged in financial brokerage until November 2020 when it shifted its primary focus to real estate and commodities as per a resolution dated May 27, 2020. The most recent quarterly results reported are for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 71 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.13 <BR>Return on Equity: -2.37% <BR>Price to Book: 11.27<BR><BR>Contact Details: <BR>Address: Desai House Survey No 2523, Costal Highway Umerasadi Killi Valsad Gujarat : 396125 <BR>Email: mbpfin@vsnl.com <BR>Website: http://www.arunis.com

Has Arunis Abode declared dividend?

No Dividend History Available

Who are the peers of the Arunis Abode?

Peers of Arunis Abode include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Elixir Capital, Ladderup Finance, Biogen Pharma, and BAMPSL Sec. Arunis Abode has the highest 1-year return at 365.82%, while Jio Financial has the lowest at -20.22%.

Peers: The peers of Arunis Abode are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Elixir Capital, Ladderup Finance, Biogen Pharma, and BAMPSL Sec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, and Muthoot Finance, while Average management risk is found at Jio Financial and Elixir Capital. Good management risk is noted at Shriram Finance, and Below Average management risk is present at Arunis Abode, Ladderup Finance, Biogen Pharma, and BAMPSL Sec. Growth is Excellent for Jio Financial, Elixir Capital, and Bajaj Finance, Good for Cholaman.Inv.&Fn and Shriram Finance, Average for Arunis Abode and Muthoot Finance, and Below Average for Ladderup Finance, Biogen Pharma, and BAMPSL Sec. Capital Structure is Excellent for Bajaj Finance, Jio Financial, Shriram Finance, Muthoot Finance, Arunis Abode, Elixir Capital, and BAMPSL Sec, Good for Biogen Pharma, and Below Average for Ladderup Finance.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Arunis Abode at 365.82%, while the lowest is Jio Financial at -20.22%. Arunis Abode's return significantly exceeds all peers. Additionally, Elixir Capital and Biogen Pharma have negative six-month returns.

What is the technical trend for Arunis Abode?

As of April 21, 2025, Arunis Abode's technical trend is mildly bullish, supported by daily moving averages and Bollinger Bands, despite mixed signals from weekly and monthly indicators.

As of 21 April 2025, the technical trend for Arunis Abode has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish, suggesting mixed signals across time frames. The RSI on a weekly basis shows no signal, but is bearish on a monthly basis. Bollinger Bands are bullish on both weekly and monthly charts, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish trend. However, the KST is mildly bearish on a weekly basis and bullish monthly, and Dow Theory shows a mildly bearish weekly trend with no trend monthly. Overall, the current technical stance is mildly bullish, driven primarily by daily moving averages and Bollinger Bands, despite some bearish signals in the weekly indicators.

How big is Arunis Abode?

As of 24th July, Arunis Abode Ltd has a market capitalization of 139.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.15 Cr in the latest four quarters. Shareholder's Funds are 6.47 Cr and Total Assets amount to 7.99 Cr as of March 2024.

As of 24th July, Arunis Abode Ltd has a market capitalization of 139.00 Cr and is classified as a Micro Cap company.<BR><BR>In the latest four quarters, Arunis Abode reported Net Sales of 0.00 Cr and a Net Profit loss of 0.15 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 6.47 Cr and Total Assets of 7.99 Cr.

Are Arunis Abode latest results good or bad?

Arunis Abode's latest results are mixed; while the company has improved its cash flow and stability, it reported the lowest operating profit in five quarters and received a 'Strong Sell' rating from analysts, indicating potential concerns for investors.

Arunis Abode's latest results present a mixed picture. On one hand, the company has shown stability with a flat performance score of 2, which is an improvement from the previous quarter's score of -2. This suggests that the company has managed to maintain its financial stability over the past three months.<BR><BR>A positive highlight is the strong operating cash flow, which reached Rs 4.47 crore, marking the highest annual operating cash flow the company has recorded. This indicates that Arunis Abode has been effective in generating cash from its business operations, which is a good sign for its financial health.<BR><BR>However, there are also concerning aspects. The operating profit (PBDIT) for the quarter was the lowest in the last five quarters at Rs -0.15 crore, indicating a negative trend in operating profit. Additionally, the stock has received a 'Strong Sell' rating from MarketsMOJO, which reflects a lack of confidence from analysts.<BR><BR>Overall, while there are some positive indicators, such as improved cash flow and stability, the low operating profit and negative analyst sentiment suggest that the results may not be viewed favorably by investors. It's essential for potential investors to weigh these factors carefully before making any decisions.

Is Arunis Abode overvalued or undervalued?

As of August 11, 2025, Arunis Abode is considered very expensive and overvalued with a PE ratio of 30.36 and a negative return on equity of -2.37%, indicating that its high valuation metrics are not justified by its financial performance compared to peers in the NBFC sector.

As of 11 August 2025, the valuation grade for Arunis Abode has moved from risky to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a PE ratio of 30.36, a Price to Book Value of 25.27, and an EV to EBITDA ratio of 31.53. These ratios are considerably higher than those of its peers, such as Life Insurance, which has a PE ratio of 11.78 and an EV to EBITDA of 9.19, highlighting the premium Arunis Abode commands despite its negative return on equity of -2.37%.<BR><BR>In comparison to other companies in the Non-Banking Financial Company (NBFC) sector, Arunis Abode's valuation metrics suggest it is not justified by its financial performance. The PEG ratio stands at an unusually low 0.03, further emphasizing the disconnect between its stock price and earnings growth potential. While the company has shown impressive returns over the past year, outperforming the Sensex significantly, the current valuation metrics indicate that investors may be overestimating its future growth prospects.

When is the next results date for Arunis Abode?

The next results date for Arunis Abode is 14 November 2025.

The next results date for Arunis Abode is scheduled for 14 November 2025.

How has been the historical performance of Arunis Abode?

Arunis Abode has experienced a significant decline in financial performance, with net sales dropping to zero by March 2025 and operating losses reported, resulting in a challenging outlook for the company. Total assets and liabilities have also decreased during this period, indicating deteriorating financial health.

Answer:<BR>The historical performance of Arunis Abode shows a significant decline in net sales and profitability over the past few years, culminating in a loss in the latest fiscal year.<BR><BR>Breakdown:<BR>Arunis Abode's net sales have decreased from 3.44 Cr in March 2023 to 0.00 Cr in March 2025, indicating a complete halt in revenue generation. Other operating income has remained consistently at 0.00 Cr throughout this period. The total operating income followed a similar trend, dropping from 3.44 Cr in March 2023 to 0.00 Cr in March 2025. Expenditures have also fluctuated, with total expenditure excluding depreciation decreasing from 2.88 Cr in March 2023 to 0.80 Cr in March 2025. Operating profit (PBDIT) turned negative at -0.28 Cr in March 2025, down from 1.10 Cr in March 2024, reflecting a severe decline in operational efficiency. Profit before tax also fell to -0.48 Cr in March 2025, compared to 0.60 Cr in March 2024. Consequently, profit after tax showed a loss of -0.15 Cr in March 2025, contrasting with a profit of 0.46 Cr in March 2024. The company's total assets decreased from 10.32 Cr in March 2022 to 7.17 Cr in March 2025, while total liabilities also fell from 10.13 Cr to 7.17 Cr during the same period. Cash flow from operating activities has been stagnant, with no cash inflow reported in the latest fiscal year. Overall, Arunis Abode's financial performance has deteriorated significantly, leading to a challenging outlook.

Should I buy, sell or hold Arunis Abode?

Which are the latest news on Arunis Abode?

Why is Arunis Abode falling/rising?

As of 04-Dec, Arunis Abode Ltd's stock price is at 155.00, reflecting a 1.97% increase. The stock has shown strong performance with a 66.81% rise over the past month and a 2982.44% increase over the past year, despite a decline in investor participation.

As of 04-Dec, Arunis Abode Ltd's stock price is rising, currently at 155.00, which reflects a change of 3.0 (1.97%) upward. This increase can be attributed to several factors. The stock has shown remarkable performance over various periods, with a 66.81% rise over the past month and an astounding 2982.44% increase over the past year. Additionally, it has been on a consecutive gain streak for the last 21 days, indicating strong upward momentum.<BR><BR>Today, the stock reached a new 52-week high of Rs. 155, and it has outperformed its sector by 1.85%. Furthermore, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a strong bullish trend. However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 18% compared to the 5-day average. Despite this decrease in participation, the overall performance metrics indicate that the stock is experiencing significant upward movement.